Emergent Biosolutions Inc (EBS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Emergent Biosolutions Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Emergent Biosolutions Inc's ROI in the second quarter of 2026?
Emergent Biosolutions Inc recorded a cumulative net loss of $-177 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -15.12%.
Within the Healthcare sector 226 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2530 to 2563.
In a move reflecting its unwavering commitment to public health, Emergent BioSolutions Inc. (NYSE: EBS) has recently secured significant funding to bolster its national preparedness initiatives. On September 26, 2024, the company announced the execution of two contract options valued at $67.4 million to procure additional treatment courses of TEMBEXA (brincidofovir). This decision underscores the U.S. government s proactive measures against potential smallpox outbreaks, emphasizing the vital role of TEMBEXA in the treatment of human smallpox disease for both adult and pediatric patients, including neonates. The new procurements are part of a larger, existing 10-year contract with the Biomedical Advanced Research and Development Authority (BARDA), illustrating a long-term commitment to maintaining a strategic health infrastructure.Emergent s recent successes did not stop there. Just weeks earlier, on September 12, 2024, the company received a contract modification worth $41.9 million for the advanced development and procurement of Ebanga (ansuvimab-zykl), a licensed treatment for Ebola virus disease (EVD). This funding, which also comes from BARDA under the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), marks a critical step toward reinforcing the efficacy and reliability of Ebanga in light of ongoing and future EVD threats.
: Emergent BioSolutions, a global life sciences company that focuses on developing and manufacturing vaccines and therapeutics, has made significant strides in its financial strategy by successfully refinancing its debt. This move is an integral part of the company s broader multi-year plan aimed at stabilizing its operations, turning around its financial performance, and ultimately transforming its business model for sustainable growth. This article examines the details surrounding this debt refinancing and its implications for the company s future. Emergent BioSolutions has been navigating a challenging economic landscape in the biopharmaceutical sector. In light of recent financial struggles, the company identified the need for a robust strategy to improve its fiscal health and operational performance. As a result, Emergent launched a comprehensive multi-year plan focused on stabilization, turnaround, and transformation. A pivotal component of this strategy was the recent successful refinancing of its debt.
Emergent BioSolutions Transfers Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals - A Strategic Move amid Changing Dynamics in the Pharmaceutical Industry
Emergent BioSolutions, a global specialty pharmaceutical company, has recently finalized the sale of its drug product facility in Baltimore-Camden to Bora Pharmaceuticals, an affiliate of Bora Pharmaceuticals Co., Ltd. This move comes amidst a rapidly evolving landscape in the pharmaceutical industry, as companies seek to realign their strategies to meet the demands of the future. The sale, valued at approximately $30 million, marks a significant strategic decision by Emergent BioSolutions to focus on its core competencies and streamline its operations. This article will delve into the implications of this transaction and its potential impact on the pharmaceutical sector. Shifting Priorities in the Pharmaceutical Industry: The pharmaceutical industry is undergoing a transformation fueled by factors such as technological advancements, changing regulatory landscape, and shifting market dynamics. In this dynamic environment, companies are continuously evaluating their portfolios and divesting non-core assets to drive efficiency and maximize profitability. Emergent BioSolutions decision to sell the Baltimore-Camden manufacturing site aligns with this industry-wide trend, allowing the company to concentrate resources on its core product offerings and strategic partnerships.
In a bid to revitalize its financial health and position itself for long-term success, Emergent BioSolutions Inc. has embarked on a multi-year transformation plan. The company, a leading player in the healthcare sector, has made significant strides in advancing its operational efficiency, reducing costs, and generating cash to increase profitability and alleviate its overall debt burden. The firm s rigorous and disciplined approach towards implementing its operational strategy is resulting in a tangible improvement in Emergent s financial position. The company s recent achievements include robust cash generation and meaningful debt repayment, confirming its commitment to this transformation plan. As a customer-focused organization, Emergent aspires to become leaner, more flexible, and better equipped to pursue strategic initiatives.
Financial Statements
Emergent Biosolutions Inc's II. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
